Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115475) titled 'A randomized controlled study of CICAPLAST BAUME B5+ in the treatment of Capecitabine- related skin Adverse Reaction in cancer patients' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Nanjing Medical University
Condition:
Cancer
Intervention:
Experimental group:Patients treated with CICAPLAST BAUME B5+
twice a day, apply to hand and feet (or adjust for specific skin adverse reactions).Follow up 8week ±3days.
Control Group:Patients treated with Silicone Oil Cream
Recruitment Status: Recruiting
Phase: N/A
Date of First E...